Merck KGaA (MRK: DE) led the way in pharmaceutical M&A in April.
The German company announced a $3.9 billion deal to buy the US drug developer SpringWorks Therapeutics in the month's biggest buy, with Swiss firm Novartis (NOVN: VX) the only other established big pharma name to acquire a company, though a host of further deals were done.
Our table and graphs below summarize the month's activity.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze